Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients: Possible translational significance

Ilaria Marech, Michele Ammendola, Rosario Sacco, Gennaro S. Capriuolo, Rosa Patruno, Rosangela Rubini, Maria Luposella, Valeria Zuccalà, Eufemia Savino, Cosmo D. Gadaleta, Domenico Ribatti, Girolamo Ranieri

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Tryptase is a serine protease released from mast cells that plays a role in tumor angiogenesis. In this study we aimed to evaluate serum tryptase levels in 105 female early breast cancer patients before (STLBS) and after (STLAS) radical surgical resection, mast cell density positive to tryptase (MCDPT) and microvascular density (MVD).Methods: STLBS and STLAS were assessed using the UniCAP Tryptase Fluoroenzyme immunoassay. Tumor sections were immunostained with a primary anti-tryptase antibody and an anti-CD-34 antibody by means of immunohistochemistry.Results: The mean ± 1 standard deviation STLBS and STLAS was 7.18 ± 2.63 μg/L, and 5.13 ± 2.21 respectively and a significant difference between mean levels was found (p = 0.0001) by student t-test. A strong correlation between STLBS and MVD (r = 0.81, p = 0.0001); STLBS and MCDPT (r = 0.69, p = 0.003); and MCDPT and MVD (r = 0.77; p = 0.0001) was found.Conclusions: Results demonstrated higher STLBS in breast cancer patients, indicating an involvement of MC tryptase in breast cancer angiogenesis. Therefore, serum tryptase levels may play a role as a novel surrogate angiogenic marker predictive of response to radical surgery in breast cancer patients. In this patients setting, it's intriguing to hypothesize that tryptase inhibitors might be evaluated in clinical trials.

Original languageEnglish
Article number534
JournalBMC Cancer
Volume14
Issue number1
DOIs
Publication statusPublished - Jul 24 2014

Fingerprint

Tryptases
Breast Neoplasms
Serum
Mast Cells
Cell Count
Serine Proteases
Immunoassay
Anti-Idiotypic Antibodies
Neoplasms
Biomarkers
Immunohistochemistry
Clinical Trials
Students

Keywords

  • Angiogenesis
  • Breast cancer
  • Mast cells
  • Serum tryptase
  • Surrogate marker
  • Tissue tryptase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics
  • Medicine(all)

Cite this

Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients : Possible translational significance. / Marech, Ilaria; Ammendola, Michele; Sacco, Rosario; Capriuolo, Gennaro S.; Patruno, Rosa; Rubini, Rosangela; Luposella, Maria; Zuccalà, Valeria; Savino, Eufemia; Gadaleta, Cosmo D.; Ribatti, Domenico; Ranieri, Girolamo.

In: BMC Cancer, Vol. 14, No. 1, 534, 24.07.2014.

Research output: Contribution to journalArticle

Marech, Ilaria ; Ammendola, Michele ; Sacco, Rosario ; Capriuolo, Gennaro S. ; Patruno, Rosa ; Rubini, Rosangela ; Luposella, Maria ; Zuccalà, Valeria ; Savino, Eufemia ; Gadaleta, Cosmo D. ; Ribatti, Domenico ; Ranieri, Girolamo. / Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients : Possible translational significance. In: BMC Cancer. 2014 ; Vol. 14, No. 1.
@article{617553a37aa64a6e939fe40936587f80,
title = "Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients: Possible translational significance",
abstract = "Background: Tryptase is a serine protease released from mast cells that plays a role in tumor angiogenesis. In this study we aimed to evaluate serum tryptase levels in 105 female early breast cancer patients before (STLBS) and after (STLAS) radical surgical resection, mast cell density positive to tryptase (MCDPT) and microvascular density (MVD).Methods: STLBS and STLAS were assessed using the UniCAP Tryptase Fluoroenzyme immunoassay. Tumor sections were immunostained with a primary anti-tryptase antibody and an anti-CD-34 antibody by means of immunohistochemistry.Results: The mean ± 1 standard deviation STLBS and STLAS was 7.18 ± 2.63 μg/L, and 5.13 ± 2.21 respectively and a significant difference between mean levels was found (p = 0.0001) by student t-test. A strong correlation between STLBS and MVD (r = 0.81, p = 0.0001); STLBS and MCDPT (r = 0.69, p = 0.003); and MCDPT and MVD (r = 0.77; p = 0.0001) was found.Conclusions: Results demonstrated higher STLBS in breast cancer patients, indicating an involvement of MC tryptase in breast cancer angiogenesis. Therefore, serum tryptase levels may play a role as a novel surrogate angiogenic marker predictive of response to radical surgery in breast cancer patients. In this patients setting, it's intriguing to hypothesize that tryptase inhibitors might be evaluated in clinical trials.",
keywords = "Angiogenesis, Breast cancer, Mast cells, Serum tryptase, Surrogate marker, Tissue tryptase",
author = "Ilaria Marech and Michele Ammendola and Rosario Sacco and Capriuolo, {Gennaro S.} and Rosa Patruno and Rosangela Rubini and Maria Luposella and Valeria Zuccal{\`a} and Eufemia Savino and Gadaleta, {Cosmo D.} and Domenico Ribatti and Girolamo Ranieri",
year = "2014",
month = "7",
day = "24",
doi = "10.1186/1471-2407-14-534",
language = "English",
volume = "14",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients

T2 - Possible translational significance

AU - Marech, Ilaria

AU - Ammendola, Michele

AU - Sacco, Rosario

AU - Capriuolo, Gennaro S.

AU - Patruno, Rosa

AU - Rubini, Rosangela

AU - Luposella, Maria

AU - Zuccalà, Valeria

AU - Savino, Eufemia

AU - Gadaleta, Cosmo D.

AU - Ribatti, Domenico

AU - Ranieri, Girolamo

PY - 2014/7/24

Y1 - 2014/7/24

N2 - Background: Tryptase is a serine protease released from mast cells that plays a role in tumor angiogenesis. In this study we aimed to evaluate serum tryptase levels in 105 female early breast cancer patients before (STLBS) and after (STLAS) radical surgical resection, mast cell density positive to tryptase (MCDPT) and microvascular density (MVD).Methods: STLBS and STLAS were assessed using the UniCAP Tryptase Fluoroenzyme immunoassay. Tumor sections were immunostained with a primary anti-tryptase antibody and an anti-CD-34 antibody by means of immunohistochemistry.Results: The mean ± 1 standard deviation STLBS and STLAS was 7.18 ± 2.63 μg/L, and 5.13 ± 2.21 respectively and a significant difference between mean levels was found (p = 0.0001) by student t-test. A strong correlation between STLBS and MVD (r = 0.81, p = 0.0001); STLBS and MCDPT (r = 0.69, p = 0.003); and MCDPT and MVD (r = 0.77; p = 0.0001) was found.Conclusions: Results demonstrated higher STLBS in breast cancer patients, indicating an involvement of MC tryptase in breast cancer angiogenesis. Therefore, serum tryptase levels may play a role as a novel surrogate angiogenic marker predictive of response to radical surgery in breast cancer patients. In this patients setting, it's intriguing to hypothesize that tryptase inhibitors might be evaluated in clinical trials.

AB - Background: Tryptase is a serine protease released from mast cells that plays a role in tumor angiogenesis. In this study we aimed to evaluate serum tryptase levels in 105 female early breast cancer patients before (STLBS) and after (STLAS) radical surgical resection, mast cell density positive to tryptase (MCDPT) and microvascular density (MVD).Methods: STLBS and STLAS were assessed using the UniCAP Tryptase Fluoroenzyme immunoassay. Tumor sections were immunostained with a primary anti-tryptase antibody and an anti-CD-34 antibody by means of immunohistochemistry.Results: The mean ± 1 standard deviation STLBS and STLAS was 7.18 ± 2.63 μg/L, and 5.13 ± 2.21 respectively and a significant difference between mean levels was found (p = 0.0001) by student t-test. A strong correlation between STLBS and MVD (r = 0.81, p = 0.0001); STLBS and MCDPT (r = 0.69, p = 0.003); and MCDPT and MVD (r = 0.77; p = 0.0001) was found.Conclusions: Results demonstrated higher STLBS in breast cancer patients, indicating an involvement of MC tryptase in breast cancer angiogenesis. Therefore, serum tryptase levels may play a role as a novel surrogate angiogenic marker predictive of response to radical surgery in breast cancer patients. In this patients setting, it's intriguing to hypothesize that tryptase inhibitors might be evaluated in clinical trials.

KW - Angiogenesis

KW - Breast cancer

KW - Mast cells

KW - Serum tryptase

KW - Surrogate marker

KW - Tissue tryptase

UR - http://www.scopus.com/inward/record.url?scp=84904528752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904528752&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-14-534

DO - 10.1186/1471-2407-14-534

M3 - Article

C2 - 25056597

AN - SCOPUS:84904528752

VL - 14

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 534

ER -